BioCentury | Oct 15, 2019
Company News

Management tracks: Gilead taps Dickinson for CFO job; plus Checkmate, BiomX, Anixa and Trio

...Inc. (NASDAQ:AGLE) while Hamburger was VP, regulatory affairs and quality assurance at Tarveda Therapeutics Inc. BiomX...
...was EVP commercialization and outcomes at ICON plc (NASDAQ:ICLR). Jonathan Block, Associate Editor Gilead Sciences Inc. Checkmate Pharmaceuticals Inc. BiomX Inc. Anixa...
BioCentury | Aug 2, 2019
Distillery Therapeutics

Gut microbe to reduce ALS severity

...DISEASE CATEGORY: Neurology INDICATION: Amyotrophic lateral sclerosis (ALS) Co-founders and collaborators of DayTwo Ltd. and BiomX...
BioCentury | Aug 1, 2019
Translation in Brief

Making connections between ALS and gut microbes

...Weizmann professors and co-founders of microbiome-based nutrition company DayTwo Ltd. Elinav is also co-founder of BiomX...
BioCentury | Jul 26, 2019
Preclinical News

July 26 preclinical Quick Takes: Ribon's new mechanism for PARP inhibitors, a microbiome-ALS link and more

...suggesting modulation of the gut microbiome could treat ALS. Elinav is also a co-founder of BiomX...
...21; PARP - Poly(ADP-ribose) polymerase; TYK2 - tyrosine kinase 2 Hongjiang Li and Sandi Wong, Staff Writers BMS-986165 BiomX Inc. Cytokinetics...
BioCentury | Jul 17, 2019
Company News

July 17 Company Quick Takes: FDA approves Merck antibiotic combo; plus PureTech, Inovio, BiomX

...papillomatosis and DNA-Encoded Bi-specific T Cell Engagers (dBTEs) programs. BiomX planning listing after reverse merger BiomX...
...Inc., Takeda Ventures and Seventure Partners. Elizabeth S. Eaton, Staff Writer, and Erin McCallister, Senior Editor BX001 Relebactam/imipenem/cilastatin FDC BiomX Inc. Inovio...
BioCentury | Jun 11, 2019
Company News

June 11 Company Quick Takes: Genmab, Janssen together again on CD38; plus GT Apeiron’s launch; BiomX, Aimmune, Keytruda

...drug discovery, with an initial focus in oncology. BiomX licenses bacterial targets for phage therapies BiomX...
...targets, including specific strains of Klebsiella pneumoniae , from JSR Corp. (Tokyo, Japan) against which BiomX...
...and Mary Romeo, Staff Writers AR101, arc001, peanut allergy oral immunotherapy (oit) Keytruda, pembrolizumab (MK-3475, lambrolizumab) Viaskin Peanut (DBV-712) BiomX Inc. DBV...
BioCentury | May 10, 2019
Targets & Mechanisms

The tumor microbiome emerges as a new source of translational opportunities

...compromised environment, and anaerobic. It makes sense bacteria can survive and thrive there.” Jonathan Solomon, BiomX...
...anaerobic. It makes sense bacteria can survive and thrive there,” said Jonathan Solomon, CEO of BiomX...
...bystander strains, which could make it more difficult to pinpoint translationally relevant strains. Solomon said BiomX...
BioCentury | Mar 14, 2019
Translation in Brief

Bacteriophages: double-edged swords

...I/II testing for infectious disease, gastrointestinal disease and cancer. Jonathan Solomon, CEO of phage company BiomX...
...disease (IBD) the team found “is somewhat speculative at this point and requires additional investigation.” BiomX...
...chronic inflammatory disease. Targets: IFNγ - Interferon γ; TLR9 - Toll-like receptor 9 Chris Lieu, Staff Writer BiomX Inc. Crohn's...
BioCentury | Mar 5, 2019
Financial News

First close for Seventure's new microbiome fund

...S.A.S. (Paris, France); LNC Therapeutics (Bordeaux, France); TargEDys (Rouen, France); A-Mansia Biotech S.A. (Louvain-la-Neuve, Belgium); BiomX...
BioCentury | Mar 1, 2019
Financial News

Seventure leads Axial's $25M series B

...has backed at least two other companies through the fund this year; on Feb. 20, BiomX...
...Bioscience S.A. (Paris, France) raised €32 million ($36.3 million) in a series D round (see “BiomX...
Items per page:
1 - 10 of 32
BioCentury | Oct 15, 2019
Company News

Management tracks: Gilead taps Dickinson for CFO job; plus Checkmate, BiomX, Anixa and Trio

...Inc. (NASDAQ:AGLE) while Hamburger was VP, regulatory affairs and quality assurance at Tarveda Therapeutics Inc. BiomX...
...was EVP commercialization and outcomes at ICON plc (NASDAQ:ICLR). Jonathan Block, Associate Editor Gilead Sciences Inc. Checkmate Pharmaceuticals Inc. BiomX Inc. Anixa...
BioCentury | Aug 2, 2019
Distillery Therapeutics

Gut microbe to reduce ALS severity

...DISEASE CATEGORY: Neurology INDICATION: Amyotrophic lateral sclerosis (ALS) Co-founders and collaborators of DayTwo Ltd. and BiomX...
BioCentury | Aug 1, 2019
Translation in Brief

Making connections between ALS and gut microbes

...Weizmann professors and co-founders of microbiome-based nutrition company DayTwo Ltd. Elinav is also co-founder of BiomX...
BioCentury | Jul 26, 2019
Preclinical News

July 26 preclinical Quick Takes: Ribon's new mechanism for PARP inhibitors, a microbiome-ALS link and more

...suggesting modulation of the gut microbiome could treat ALS. Elinav is also a co-founder of BiomX...
...21; PARP - Poly(ADP-ribose) polymerase; TYK2 - tyrosine kinase 2 Hongjiang Li and Sandi Wong, Staff Writers BMS-986165 BiomX Inc. Cytokinetics...
BioCentury | Jul 17, 2019
Company News

July 17 Company Quick Takes: FDA approves Merck antibiotic combo; plus PureTech, Inovio, BiomX

...papillomatosis and DNA-Encoded Bi-specific T Cell Engagers (dBTEs) programs. BiomX planning listing after reverse merger BiomX...
...Inc., Takeda Ventures and Seventure Partners. Elizabeth S. Eaton, Staff Writer, and Erin McCallister, Senior Editor BX001 Relebactam/imipenem/cilastatin FDC BiomX Inc. Inovio...
BioCentury | Jun 11, 2019
Company News

June 11 Company Quick Takes: Genmab, Janssen together again on CD38; plus GT Apeiron’s launch; BiomX, Aimmune, Keytruda

...drug discovery, with an initial focus in oncology. BiomX licenses bacterial targets for phage therapies BiomX...
...targets, including specific strains of Klebsiella pneumoniae , from JSR Corp. (Tokyo, Japan) against which BiomX...
...and Mary Romeo, Staff Writers AR101, arc001, peanut allergy oral immunotherapy (oit) Keytruda, pembrolizumab (MK-3475, lambrolizumab) Viaskin Peanut (DBV-712) BiomX Inc. DBV...
BioCentury | May 10, 2019
Targets & Mechanisms

The tumor microbiome emerges as a new source of translational opportunities

...compromised environment, and anaerobic. It makes sense bacteria can survive and thrive there.” Jonathan Solomon, BiomX...
...anaerobic. It makes sense bacteria can survive and thrive there,” said Jonathan Solomon, CEO of BiomX...
...bystander strains, which could make it more difficult to pinpoint translationally relevant strains. Solomon said BiomX...
BioCentury | Mar 14, 2019
Translation in Brief

Bacteriophages: double-edged swords

...I/II testing for infectious disease, gastrointestinal disease and cancer. Jonathan Solomon, CEO of phage company BiomX...
...disease (IBD) the team found “is somewhat speculative at this point and requires additional investigation.” BiomX...
...chronic inflammatory disease. Targets: IFNγ - Interferon γ; TLR9 - Toll-like receptor 9 Chris Lieu, Staff Writer BiomX Inc. Crohn's...
BioCentury | Mar 5, 2019
Financial News

First close for Seventure's new microbiome fund

...S.A.S. (Paris, France); LNC Therapeutics (Bordeaux, France); TargEDys (Rouen, France); A-Mansia Biotech S.A. (Louvain-la-Neuve, Belgium); BiomX...
BioCentury | Mar 1, 2019
Financial News

Seventure leads Axial's $25M series B

...has backed at least two other companies through the fund this year; on Feb. 20, BiomX...
...Bioscience S.A. (Paris, France) raised €32 million ($36.3 million) in a series D round (see “BiomX...
Items per page:
1 - 10 of 32